# Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

> **NCT02164539** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 338 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** FF
- **DRUG:** UMEC
- **DRUG:** VI

## Key facts

- **NCT ID:** NCT02164539
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-01
- **Primary completion:** 2015-07-01
- **Final completion:** 2015-07-18
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2017-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02164539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02164539, "Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02164539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*